Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/51697 |
Resumo: | Programa ‘Fazer o bem faz bem". Conselho Nacional de Pesquisa do Brasil (CNPq). Fundação Carlos Chagas Filho de Amparo. Pesquisa do Estado do Rio de Janeiro. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. Senior Clinical Fellowship. Medical Research Council. Scottish Government Chief Scientist Office. Data and Connectivity National Core Study. Health Data Research UK. Office for National Statistics. UK Research and Innovation. National Institute for Health Research |
| id |
CRUZ_8d807a7ecee055dcf5de0132427e13c3 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/51697 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Silva, Thiago CerqueiraKatikireddi, Srinivasa VittalOliveira, Vinicius de AraujoOrtiz, Renzo FloresBertoldo Júnior, JuracyPaixão, Enny S.Robertson, ChrisPenna, Gerson O.Werneck, Guilherme L.Barreto, Maurício L.Pearce, NeilSheikh, AzizBarral Netto, ManoelBoaventura, Viviane S.2022-03-15T14:38:35Z2022-03-15T14:38:35Z2022Silva, T. Cerqueira. et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nature Medicine, p. 1-20, 2022.1546-170Xhttps://www.arca.fiocruz.br/handle/icict/5169710.1038/s41591-022-01701-wPrograma ‘Fazer o bem faz bem". Conselho Nacional de Pesquisa do Brasil (CNPq). Fundação Carlos Chagas Filho de Amparo. Pesquisa do Estado do Rio de Janeiro. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. Senior Clinical Fellowship. Medical Research Council. Scottish Government Chief Scientist Office. Data and Connectivity National Core Study. Health Data Research UK. Office for National Statistics. UK Research and Innovation. National Institute for Health ResearchFundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Enfermidades Infecciosas Transmitidas por Vetores. Laboratório de Inflamação e Biomarcadores. Salvador, BA, Brasil / Universidade Federal de Bahia. Salvador, BA, Brasil.MRC/CSO Social and Public Health Sciences Unit. University of Glasgow. Glasgow, UK / Public Health Scotland. Glasgow, UK.Universidade Federal de Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil.Fundação Oswaldo Cruz Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil.Universidade Federal de Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil.London School of Hygiene and Tropical Medicine. London, UK.Public Health Scotland. Glasgow, UK / Department of Mathematics and Statistics. University of Strathclyde, Glasgow, UK.Universidade de Brasília. Escola Fiocruz de Governo. Núcleo de Medicina Tropical. Rio de Janeiro, RJ, Brasil.Universidade do Estado do Rio de Janeiro. Rio de Janeiro, RJ, Brasil.Universidade Federal de Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil.London School of Hygiene and Tropical Medicine. London, UK.Usher Institute, University of Edinburgh, Edinburgh, UK.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Enfermidades Infecciosas Transmitidas por Vetores. Laboratório de Inflamação e Biomarcadores Salvador, BA, Brasil / Universidade Federal de Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Enfermidades Infecciosas Transmitidas por Vetores. Laboratório de Inflamação e Biomarcadores Salvador, BA, Brasil / Universidade Federal de Bahia. Salvador, BA, Brasil.There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of BNT162b2 booster vaccination against RT–PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death). Compared with unvaccinated individuals, CoronaVac VE at 14–30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3–55.7) against confirmed infection and 82.1% (95% CI: 81.4–82.8) against severe outcomes. VE decreased to 34.7% (95% CI: 33.1–36.2) against infection and 72.5% (95% CI: 70.9–74.0) against severe outcomes over 180 d after the second dose. A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0−94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1−98.1) 14–30 d after the booster. Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster. Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly.engNature ResearchCOVID-19VacinasTeste de Ácido NucleicoCOVID-19VaccinesNucleic Acid TestingCOVID-19VacunasPrueba de Ácido NucleicoCoronavirusVaccinsVaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/51697/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALSilva, T C - Vaccine effectiveness.pdfSilva, T C - Vaccine effectiveness.pdfapplication/pdf3766329https://www.arca.fiocruz.br/bitstream/icict/51697/2/Silva%2c%20T%20C%20-%20Vaccine%20effectiveness.pdf8cc9d79015334307437c07ec20c70018MD52icict/516972023-03-15 14:34:35.288oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:35Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil |
| title |
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil |
| spellingShingle |
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil Silva, Thiago Cerqueira COVID-19 Vacinas Teste de Ácido Nucleico COVID-19 Vaccines Nucleic Acid Testing COVID-19 Vacunas Prueba de Ácido Nucleico Coronavirus Vaccins |
| title_short |
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil |
| title_full |
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil |
| title_fullStr |
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil |
| title_full_unstemmed |
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil |
| title_sort |
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil |
| author |
Silva, Thiago Cerqueira |
| author_facet |
Silva, Thiago Cerqueira Katikireddi, Srinivasa Vittal Oliveira, Vinicius de Araujo Ortiz, Renzo Flores Bertoldo Júnior, Juracy Paixão, Enny S. Robertson, Chris Penna, Gerson O. Werneck, Guilherme L. Barreto, Maurício L. Pearce, Neil Sheikh, Aziz Barral Netto, Manoel Boaventura, Viviane S. |
| author_role |
author |
| author2 |
Katikireddi, Srinivasa Vittal Oliveira, Vinicius de Araujo Ortiz, Renzo Flores Bertoldo Júnior, Juracy Paixão, Enny S. Robertson, Chris Penna, Gerson O. Werneck, Guilherme L. Barreto, Maurício L. Pearce, Neil Sheikh, Aziz Barral Netto, Manoel Boaventura, Viviane S. |
| author2_role |
author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Silva, Thiago Cerqueira Katikireddi, Srinivasa Vittal Oliveira, Vinicius de Araujo Ortiz, Renzo Flores Bertoldo Júnior, Juracy Paixão, Enny S. Robertson, Chris Penna, Gerson O. Werneck, Guilherme L. Barreto, Maurício L. Pearce, Neil Sheikh, Aziz Barral Netto, Manoel Boaventura, Viviane S. |
| dc.subject.other.pt_BR.fl_str_mv |
COVID-19 Vacinas Teste de Ácido Nucleico |
| topic |
COVID-19 Vacinas Teste de Ácido Nucleico COVID-19 Vaccines Nucleic Acid Testing COVID-19 Vacunas Prueba de Ácido Nucleico Coronavirus Vaccins |
| dc.subject.en.pt_BR.fl_str_mv |
COVID-19 Vaccines Nucleic Acid Testing |
| dc.subject.es.pt_BR.fl_str_mv |
COVID-19 Vacunas Prueba de Ácido Nucleico |
| dc.subject.fr.pt_BR.fl_str_mv |
Coronavirus Vaccins |
| description |
Programa ‘Fazer o bem faz bem". Conselho Nacional de Pesquisa do Brasil (CNPq). Fundação Carlos Chagas Filho de Amparo. Pesquisa do Estado do Rio de Janeiro. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior. Senior Clinical Fellowship. Medical Research Council. Scottish Government Chief Scientist Office. Data and Connectivity National Core Study. Health Data Research UK. Office for National Statistics. UK Research and Innovation. National Institute for Health Research |
| publishDate |
2022 |
| dc.date.accessioned.fl_str_mv |
2022-03-15T14:38:35Z |
| dc.date.available.fl_str_mv |
2022-03-15T14:38:35Z |
| dc.date.issued.fl_str_mv |
2022 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
Silva, T. Cerqueira. et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nature Medicine, p. 1-20, 2022. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/51697 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1546-170X |
| dc.identifier.doi.none.fl_str_mv |
10.1038/s41591-022-01701-w |
| identifier_str_mv |
Silva, T. Cerqueira. et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nature Medicine, p. 1-20, 2022. 1546-170X 10.1038/s41591-022-01701-w |
| url |
https://www.arca.fiocruz.br/handle/icict/51697 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Nature Research |
| publisher.none.fl_str_mv |
Nature Research |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/51697/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/51697/2/Silva%2c%20T%20C%20-%20Vaccine%20effectiveness.pdf |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 8cc9d79015334307437c07ec20c70018 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009131275026432 |